Brief: Freeline Doses Second Patient Of Phase 1/2 Marvel-1 Clinical Trial For Fabry Disease

Freeline Therapeutics Holdings

16/06/2021 12:49

June 16 (Reuters) - Freeline Therapeutics Holdings PLC
 FRLN.O :
    * FREELINE DOSES SECOND PATIENT OF PHASE 1/2 MARVEL-1
CLINICAL
TRIAL FOR FABRY DISEASE
    * FREELINE DOSES SECOND PATIENT OF PHASE 1/2 MARVEL-1
CLINICAL
TRIAL FOR FABRY DISEASE
    * FREELINE THERAPEUTICS - COMPANY TO PRESENT FLT190 DATA BY
YEAR-END

Source text for Eikon:  ID:nGNX6vHVMb 
Further company coverage:  FRLN.O 

 ((Reuters.Briefs@thomsonreuters.com;))